REPLY 200

Extending the boundaries in cardiovascular disease management.

Healthcare Professionals Cardiac Rhythm Management Pacemakers REPLY 200

REPLY 200

The world’s smallest pacemaker1

A pacemaker with Sleep Apnea Monitoring. Extending the boundaries in cardiovascular disease management.

Reply 200 automatically screens patients at risk of severe sleep apnea, featuring a suite of algorithms designed to prevent serious cardiovascular comorbidities.

12 years longevity in only 8 cc.

The world’s smallest dual-chamber pacemaker with no compromise on longevity.1–3

REPLY 200 REPLY 200 DR Micro Port 2018 1
Safer

SafeR™

Dramatically reduces unnecessary RV pacing in all pacemaker patients, including AV block patients.

Discover this therapy
Dual

Dual Sensor™

Designed to physiologically modulate heart rhythm by combining Accelerometer and Minute Ventilation sensors.

Discover this therapy
SAM

SAM™

Sleep Apnea Monitoring measures respiration pauses and reduction in respiration.

Discover this therapy

Powered by intelligent algorithms

SafeR™

  • Advanced AV management for increased protection4,6–12
  • Reduces RV pacing in SND and AVB patients4
  • Manages ALL types of AV blocks at rest and at exercise2,4
  • Adds 2 YEARS of device longevity11,12
  • Unique AV block diagnosis
REPLY 200 Kora3 1

Dual sensorTM

  • Adjust to metabolic needs. Exercise safely
  • Designed to physiologically modulate the heart rhythm by combining Accelerometer and Minute Ventilation sensors

Sleep Apnea MonitoringTM

  • Early detection, long-term risk reduction2,5,13–17
  • Reliable screening to detect severe sleep apnea with high specificity (85%) and high sensitivity (89%)5
  • Correlated with gold standard Apnea–Hypopnea Index*5
  • Designed to monitor the evolution of sleep apnea2

*Apnea Hypopnea Index (AHI) = number of events/number of hours of sleep

REPLY 200 Kora4 2

This product is not available for sale or distribution in the USA. For further information on product availability, please contact your local representative.

REFERENCES

  1. Competition comparison across transvenous pacing systems made as of September 2020, refer to manufacturers manuals available online
  2. Sorin implant manuals (Reply 200 – U071 – U072) available at www.microportmanuals.com
  3. Reply 200 with typical conditions using SafeR: 50% A pacing, 5% V pacing, SAM ON, 60 bpm, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics ON, Sensors ON.
  4. Stockburger M, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in general population (ANSWER study). European Heart Journal. 2015;36:151–57.
  5. Defaye P, et al. A pacemaker transthoracic impedance sensor with an advanced algorithm to identify severe sleep apnea: The DREAM European study. Heart Rhythm. 2014; 11: 842–48.
  6. Andersen HR, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210–6.
  7. Skanes AC, et al. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing (CTOPP). J Am Coll Cardiol. 2001;38:167–72.
  8. Nielsen J, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol. 2003;42:614–23.
  9. Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003; 107: 2932–37.
  10. Wilkoff BL, Cook JR, Epstein AE et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID trial). JAMA. 2002; 288: 3115–23.
  11. Stockburger M, Defaye P, Boveda S et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a substudy of the ANSWER trial. Europace 2016; 18:739–46.
  12. Benkemoun H, et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry. Pacing Clin Electrophysiol 2012;35:403–08.
  13. Gottlieb DJ, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352–60.
  14. Mehra R, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2006;173:910–16.
  15. Monahan K, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110:369–72.
  16. Kanagala R, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107:2589–94.
  17. Ng CY, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108:47–51.